<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198207</url>
  </required_header>
  <id_info>
    <org_study_id>TRE-VNS</org_study_id>
    <nct_id>NCT04198207</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Vagus Nerve Stimulation for TRE</brief_title>
  <official_title>Clinical Evaluation of the Effectiveness and Safety of Vagus Nerve Stimulation for Tuberous Sclerosis Complex Related Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanbo Brain Hospital Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Medical Center of PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Institute of Pediatrics, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiamen Humanity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Medical Care Center for Women and Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong 999 Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital, Army Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Children's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective controlled studies to identify clinical epilepsy control, cognitive changes, and
      safety in VNS treatment of tuberculosis-related epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control group: no clear epilepsy focus in the brain, and medication has been continued.

      Surgery group: no clear epilepsy focus in the brain, and VNS for tuberculosis-related
      epilepsy.

      In order to ensure the follow-up of the study and 3 years after the end of the study, 50
      cases were collected in each group of the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>% of patients with ILAE grading</measure>
    <time_frame>3 years</time_frame>
    <description>The grading made by ILAE for the classification of outcome with respect to epileptic seizures following epilepsy surgery. It contains a total of 6 levels. The higher the level, the worse the result. We will count the percentage of patients at each level.epileptic seizures following epilepsy surgery. It is used for assessing the control of epilepsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IQ</measure>
    <time_frame>3 years</time_frame>
    <description>Wechsler Intelligence Scale is used for the evaluation of IQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: QOLIE-31</measure>
    <time_frame>3 years</time_frame>
    <description>QOLIE-31 is suitable for patients 14 years and older. QOLCE-76 is applied to patients aged 2-13 by parents.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tuberous Sclerosis Complex</condition>
  <condition>Epilepsy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from participating medical institutions
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 years old and above, no gender restriction, TSC gene monitoring with or without
             abnormality

          -  Diagnosis of nodular sclerosis and epilepsy

          -  Epilepsy course for more than 1 year

          -  Patients who have taken 3 or more reasonable choices with appropriate and tolerable
             antiepileptic drugs (excluding mTOR inhibitors and traditional Chinese medicine and
             prescriptions) had seizures more than 12 times in the 3 months before enrollment

          -  The family members agreed to enroll and signed the informed consent.

        Exclusion Criteriaï¼š

          -  Obvious renal angiomyolipoma, pulmonary lymphoma leiomyomatosis, and subventricular
             giant cell astrocytoma

          -  Abnormal heart, lung, liver, and kidney functions and coagulation function

          -  The family did not sign the informed consent

          -  Preoperative evaluation, it is considered that no surgical treatment is needed

          -  The patient received other craniocerebral surgical treatment within 1 year during the
             follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Children's Hospital</investigator_affiliation>
    <investigator_full_name>Shuli Liang</investigator_full_name>
    <investigator_title>Director of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>tuberous sclerosis complex</keyword>
  <keyword>epilepsy</keyword>
  <keyword>vagus nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

